Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Ann Pharm Fr ; 82(5): 898-904, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38759885

RESUMO

OBJECTIVES: Acetaminophen is the most widely antipyretic analgesic medicine used in adults and children worldwide. Rectal acetaminophen is widely used in children who resist or cannot take oral medications. This study was designed to compare the efficacy of rectal and IV acetaminophen in children with fever and mild to moderate pain. PATIENTS AND METHODS: Total 60 children aged six months to 6 years, with fever and pain, that were treated with rectal or intravenous acetaminophen were selected and assigned in two groups. The IV group received 10mg/kg paracetamol as an IV infusion, and the rectal group received a 15mg/kg dose immediately after admission. Pain score was calculated using the FLACC method, and the axillary temperature was recorded at baseline and then 0.5, 1, 2, 4, and 6hours after drug administration. Blood samples were collected at baseline and then at 30min-intervals for the first 90minutes. RESULTS: The trend of changes in mean pain score at different time intervals was significantly different between the two groups. Body temperature decrease was more prominent in the IV group. The plasma concentration increased in both groups significantly with time. This increase was sharper in the IV group, just in the first 60minutes after drug administration. CONCLUSIONS: IV acetaminophen has more rapid onset of action, while rectal dosage form control fever and pain for longer duration. Considering its favorable effects with ease of administration and lower cost, rectal acetaminophen can be a reasonable option in selected patients with pain or fever.


Assuntos
Acetaminofen , Administração Retal , Analgésicos não Narcóticos , Antipiréticos , Febre , Dor , Humanos , Acetaminofen/administração & dosagem , Acetaminofen/uso terapêutico , Acetaminofen/sangue , Masculino , Pré-Escolar , Feminino , Criança , Lactente , Antipiréticos/administração & dosagem , Antipiréticos/uso terapêutico , Irã (Geográfico) , Febre/tratamento farmacológico , Analgésicos não Narcóticos/administração & dosagem , Analgésicos não Narcóticos/uso terapêutico , Dor/tratamento farmacológico , Administração Intravenosa , Medição da Dor , Temperatura Corporal/efeitos dos fármacos , Infusões Intravenosas
2.
Ann Pharm Fr ; 81(6): 977-984, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37619945

RESUMO

BACKGROUND: Since the 2019 COVID-19 pandemic is not the first and will not be the last, pharmacists' experiences during this period can be used to establish a more efficient healthcare system to face future pandemics. OBJECTIVE: This study aims to explore Iranian pharmacists' experiences in pharmacies using the content analysis method. METHODS: In this qualitative study, a conventional content analysis approach was applied. Ten male and female pharmacists working in community pharmacies in Birjand, Iran participated using a purposeful sampling method. Semi-structured interviews were carried out for data collection. The data were analyzed using Graneheim and Lundman's method. RESULTS: Four categories and ten subcategories were extracted as follows: Multifaceted concerns of pharmacists (familial, economical, professional, and personal concerns), Non-compliance with protocols from occurrence to cause (facing non-compliance with protocols by clients, obstacles to complying with protocols in the pharmacy), Prevention from COVID-19 (protective equipment usage, designing protection rules), and Double reactions to COVID-19 (emotional and; practical reactions). CONCLUSIONS: Pharmacists dealt with different concerns and challenges during the COVID-19 pandemic. They are one of the main primary care providers and need to be supported by the authorities to maintain their standard level of services.

3.
Heart Fail Rev ; 25(6): 993-1006, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-31745839

RESUMO

Despite various individual studies on the quality of life (QOL) in patients with CHF, a comprehensive study has not yet been conducted; therefore, this study aims to assess the QOL of CHF patients. In the present systematic review and meta-analysis, PubMed, Scopus, and the Web of science databases were searched from January 1, 2000, to December 31, 2018, using QOL and heart failure as keywords. The searches, screenings, quality assessments, and data extractions were conducted separately by two researchers. A total of 70 studies including 25,180 participants entered the final stage. The mean QOL score was 44.1 (95% confidence interval (CI) 40.6, 47.5; I2 = 99.3%) using a specific random effects method in 40 studies carried out on 12,520 patients. Moreover, according to the geographical region, heart failure patients in the Americas had higher scores. In 14 studies, in which a general SF-36 survey was implemented, the average physical component score (PCS) and mental component score (MCS) were 33.3 (95% CI 31.9, 34.7; I2 = 88.0%) and 50.6 (95% CI 43.8, 57.4; I2 = 99.3%), respectively. The general and specific tools used in this study indicated moderate and poor QOL, respectively. Therefore, it is necessary to carry out periodic QOL measurements using appropriate tools as part of the general care of CHF patients.


Assuntos
Insuficiência Cardíaca/psicologia , Qualidade de Vida , Humanos
4.
Curr Probl Cardiol ; 47(6): 100848, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-34006389

RESUMO

The present study aimed to evaluate the prevalence of depression among heart failure (HF) patients. Depression is one of the main risk factors of mortality and reduction in quality of life in patients with HR. Despite individual studies, there is no comprehensive study on depression in HF patients. In the present systematic review and meta-analysis, databases (Web of Science, Scopus, and PubMed) were searched from January 1, 2000, to December 15, 2020. The keywords used included: depression and heart failure. The research stages including search, screening, quality evaluation, and extraction of study data were performed separately by two researchers. A total of 149 studies performed on 305,407 HF patients entered the final stage. The global prevalence of any severity and moderate to severe severity of depression was 41.9% and 28.1%, respectively. The results of the subgroup analysis showed that the prevalence of depression was higher in women (45.5%) than in men. Also, according to the NHYA classification, the prevalence of depression in patients in stages three and four (54.7%) was higher than stages 1 and 2. The prevalence of depression was higher in the EMRO region (70.1%) and lower economic status countries (56.7%).The high prevalence of depression among HF patients indicates the importance of paying more attention and providing the necessary training for patients to reduce depression.


Assuntos
Insuficiência Cardíaca , Qualidade de Vida , Depressão/epidemiologia , Feminino , Insuficiência Cardíaca/etiologia , Humanos , Masculino , Prevalência , Fatores de Risco
5.
Complement Ther Med ; 49: 102318, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32147038

RESUMO

OBJECTIVE: This systematic review aimed to evaluate the efficacy of CAM interventions for cancer-related pain in breast cancer patients. METHODS: Databases (PubMed, Scopus, Web of Science, and EMBASE) were searched from January 1, 2000, up to April 31, 2019, using the keywords: Complementary and alternative medicine therapies and cancer related pain. Standard tools were used to evaluate the quality of the studies included. RESULTS: Of the 3742 articles found, 46 articles comprising 3685 participants entered the final phase. Our results indicate that interventions including acupuncture/acupressure, tai chi/qi gong, hypnosis, meditation, music therapy, yoga, massage, reflexology, and Reiki improve cancer-related pain in breast cancer patients. However, aromatherapy had no effect on the same. CONCLUSIONS: Despite the positive effect of various CAM interventions in reducing cancer-related pain, necessary precautions should be adopted to use them alongside other treatments to control cancer pain in the clinical setting.


Assuntos
Neoplasias da Mama/complicações , Dor do Câncer/etiologia , Dor do Câncer/terapia , Terapias Complementares/métodos , Feminino , Humanos
6.
Hum Exp Toxicol ; 26(9): 697-703, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17984140

RESUMO

In acute respiratory distress syndrome (ARDS), there is extensive overproduction of free radicals to the extent that endogenous anti-oxidants are overwhelmed, permitting oxidative cell damage. The present study examined the benefit of the anti-oxidant compound N-acetylcysteine (NAC) in the management of ARDS by measuring patient's intracellular glutathione (inside red blood cells) and extracellular (plasma) anti-oxidant defense biomarkers and outcome. Twenty-seven ARDS patients were recruited from the intensive care unit of a teaching Hospital and randomly divided into two groups. Both groups were managed similarly by regular treatments but 17 patients received NAC 150 mg/kg at the first day that followed by 50 mg/kg/day for three days and 10 patients did not receive NAC. Treatment by NAC increased extracellular total anti-oxidant power and total thiol molecules and also improved intracellular glutathione and the outcome of the patients. In conclusion, patients with ARDS are in a deficient oxidant-anti-oxidant balance that can get a significant benefit if supplemented with NAC.


Assuntos
Acetilcisteína/uso terapêutico , Antioxidantes/uso terapêutico , Plaquetas/efeitos dos fármacos , Glutationa/sangue , Estresse Oxidativo/efeitos dos fármacos , Síndrome do Desconforto Respiratório/tratamento farmacológico , Compostos de Sulfidrila/sangue , APACHE , Acetilcisteína/administração & dosagem , Adulto , Antioxidantes/administração & dosagem , Antioxidantes/metabolismo , Biomarcadores/sangue , Plaquetas/metabolismo , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Síndrome do Desconforto Respiratório/sangue , Síndrome do Desconforto Respiratório/metabolismo , Resultado do Tratamento , Regulação para Cima
7.
Springerplus ; 5(1): 1749, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27795892

RESUMO

BACKGROUND: Drug use evaluation is a performance improvement method that evaluates medication-use processes. Medication studies are especially important for drugs with narrow therapeutic index, specific indication, high costs as well as for drugs with widespread use. Intravenous pantoprazole always ranked among the top 5 costly drugs in Amir-al-Momenin Hospital. Considering the fact that widespread and inappropriate use of this drug is considered as a concern in hospitals all over the world rather than being a regional problem, we decided to establish a guideline for intravenous (IV) pantoprazole in our hospital and evaluated the pattern of its administration both before and after establishing the guideline. METHODS: This is an experimental study (clinical trial) performed at the Amir-al-Momenin Hospital, on 400 randomly selected patients receiving IV pantoprazole (bolus or infusion) during a 6-month period (3 months before and 3 months after establishing guideline). We used predesigned data collection forms to collect related information. We used SPSS Ver. 18 for statistical analysis. RESULTS: Our results showed that the established guideline could significantly reduce the rate (P = 0.00) and cost (301,289,000 Rials or 8608 USD in 3 months study period after establishing guideline) of IV pantoprazole administration, but failed to rectify indications and dosage of its administration at the same rate. Stress ulcer prophylaxis was the most frequent approved indication for IV pantoprazole administration in our study population. We also observed that the rate of commitment to the guideline decreased by the time passed from its establishment. CONCLUSION: We concluded that although establishing guideline was successful in reducing the overall rate of IV pantoprazole administration and its related costs, different contributing factors halted its effect on correcting the prescribed dosage and indications, especially as the time gaps from guideline establishment. This fact magnifies the importance of continuous educations of prescribers about the importance of evidence based practice and need for and implementing a powerful executive supervisory in our hospital.

8.
Adv Pharmacol Sci ; 2015: 507151, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26064103

RESUMO

Background. Heparin, used clinically as an anticoagulant, also has anti-inflammatory properties. The purpose of this systematic review was to provide a comprehensive review regarding the efficacy and safety of heparin and its derivatives as anti-inflammatory agents. Methods. We searched the following databases up to March 2012: Pub Med, Scopus, Web of Science, Ovid, Elsevier, and Google Scholar using combination of Mesh terms. Randomized Clinical Trials (RCTs) and trials with quasi-experimental design in clinical setting published in English were included. Quality assessments of RCTs were performed using Jadad score and Consolidated Standards of Reporting Trials (CONSORT) checklist. Results. A total of 280 relevant studies were reviewed and 57 studies met the inclusion criteria. Among them 48 studies were RCTs. About 65% of articles had score of 3 and higher according to Jadad score. Twelve studies had a quality score > 40% according to CONSORT items. Asthma (n = 7), inflammatory bowel disease (n = 5), cardiopulmonary bypass (n = 8), and cataract surgery (n = 6) were the most studied disease condition. Forty studies use unfractionated heparin (UFH) for intervention; the remaining studies use low molecular weight heparin (LMWH). Conclusion. Despite the conflicting results, heparin seems to be a safe and effective anti-inflammatory agent; although it is shown that heparin can decrease the level of inflammatory biomarkers and improves patient conditions, still more data from larger rigorously designed studies are needed to support use of heparin as an anti-inflammatory agent in clinical setting. However, because of the association between inflammation, atherogenesis, thrombogenesis, and cell proliferation, heparin and related compounds with pleiotropic effects may have greater therapeutic efficacy than compounds acting against a single target.

9.
Iran J Pharm Res ; 12(Suppl): 161-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24250684

RESUMO

Drug Utilization Evaluation (DUE) studies are designed to assess drug usage appropriateness. We aim to evaluate the drug utilization of intravenous ciprofloxacin and imipenem, two of the broad spectrum antibiotics that consume a significant proportion of our hospitals' outlay, in different wards of a teaching hospital in Zabol. During a 5 months period (December 2010 to May 2011), 263 patients who received imipenem or intravenous ciprofloxacin were assigned to this study. Retrospective review of patient's records was carried out. Data were converted to Defined Daily Dose (DDD) and the ratio of prescribed daily dose per DDD was calculated. Among these records, 100 patients received either imipenem or ciprofloxacin. The ratio of prescribed daily dose to DDD was 1.5 for both antibiotics. Almost all patients received empiric therapy in both groups. Only 13 patients (26%) in ciprofloxacin group and 4 patients (8%) in imipenem group received their antibiotics consistent with American Hospital Formulary System (AHFS) mentioned indication. Baseline Blood Urea Nitrogen (BUN) and serum Creatinine were ordered for only 37 patients (74%) in both groups with 15 abnormal results but dose adjustment performed just in one case with decreased renal function. In conclusion, the majority of courses with both drugs were empirically selected and continued and required lab tests for drug monitoring and dose adjustments were not performed in most cases. Educational interventions, developing a local formulary and a strict antibiotic prescribing policy for example by prior approval by an infectious disease consultant can help significantly to overcome these problems.

10.
Respir Med ; 103(3): 434-41, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18993042

RESUMO

Oxidative stress has a proven role in pathophysiology of acute respiratory distress syndrome. The antioxidant drugs, especially N-acetylcysteine (NAC) have been used for years to overcome oxidative stress effects in patients. In the present study we have investigated the effects of NAC treatment (IV NAC in 150mg/kg at the first day followed by 50mg/kg/day for three days) on 27 ICU patients with ALI/ARDS considering the glutathione-S-transferase genetic variations, as an important enzyme contributing in oxidative stress pathways. The results indicated that NAC improved oxygenation (increase in PaO(2)/FiO(2)) and decreased mortality rate in treated patients compared to control group (p<0.05). Evaluation of three isoforms of glutathione-S-transferase (GST M1, P1 and T1), in these patients have showed an association between GST M1 null, and GST M1 and T1 double null polymorphisms with increased mortality in control group, suggesting antioxidant therapy critical for this group of patients.


Assuntos
Acetilcisteína/administração & dosagem , Lesão Pulmonar Aguda/tratamento farmacológico , Antioxidantes/administração & dosagem , Glutationa Transferase/genética , Polimorfismo Genético , Síndrome do Desconforto Respiratório/tratamento farmacológico , Acetilcisteína/uso terapêutico , Lesão Pulmonar Aguda/genética , Lesão Pulmonar Aguda/mortalidade , Adulto , Antioxidantes/uso terapêutico , Estudos de Casos e Controles , Distribuição de Qui-Quadrado , Esquema de Medicação , Feminino , Frequência do Gene , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo , Síndrome do Desconforto Respiratório/genética , Síndrome do Desconforto Respiratório/mortalidade , Método Simples-Cego , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA